INTI Inhibitor Therapeutics, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1042418 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.0%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-188.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,373.4%
Debt / equity—
Current ratio0.53x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-21.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $228,341 | $223,564 | $340,562 | $757,248 | $377,789 | $325,623 | $236,058 | $887,794 |
| SG&A expense | $363,684 | $395,033 | $355,070 | $557,866 | $363,426 | $370,150 | $438,493 | $596,455 |
| Operating income | -$592,025 | -$618,597 | -$695,632 | -$1.32M | -$741,215 | -$695,773 | -$674,551 | -$1.48M |
| Net income | -$590,380 | -$613,933 | -$686,425 | -$1.30M | -$712,184 | -$659,942 | -$632,846 | -$1.42M |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 173.79M | 173.31M | 172.57M | — | 172.57M | 172.57M | 172.32M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $146,193 | $515,758 | $1.29M | $2.38M | $2.98M | $3.74M | $4.32M | $5.61M |
| Current assets | $204,123 | $586,806 | $1.38M | $2.45M | $3.06M | $3.83M | $4.42M | $5.69M |
| Total assets | $247,348 | $637,190 | $1.43M | $2.51M | $3.14M | $3.91M | $4.51M | $5.69M |
| Current liabilities | $383,394 | $174,894 | $382,320 | $766,330 | $87,533 | $139,961 | $94,712 | $709,618 |
| Short-term debt | $30,577 | $26,262 | $28,981 | $24,724 | $27,455 | $25,987 | $25,987 | — |
| Long-term debt | $13,604 | $21,566 | $29,380 | $36,889 | $44,181 | $52,064 | $58,361 | — |
| Total debt | $44,181 | $47,828 | $58,361 | $61,613 | $71,636 | $78,051 | $84,348 | — |
| Total liabilities | $3.40M | $3.20M | $3.41M | $3.80M | $3.13M | $3.19M | $3.15M | $3.71M |
| Shareholders' equity | -$3.15M | -$2.56M | -$1.98M | -$1.29M | $3,453 | $715,637 | $1.35M | $1.99M |
| Net debt | -$102,012 | -$467,930 | -$1.23M | -$2.31M | -$2.91M | -$3.66M | -$4.24M | — |
| Shares outstanding | 173.79M | 173.79M | 172.57M | 172.57M | 172.57M | 172.57M | 172.32M | 172.32M |
| Cash flow statement | ||||||||
| Operating cash flow | -$369,565 | -$775,220 | -$1.08M | -$601,165 | -$761,245 | -$583,991 | -$1.28M | -$771,441 |
| Stock-based compensation | $0 | — | — | $0 | $0 | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 57 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.